Brief: Avidity Biosciences Announces Positive Pre-BLA Meeting With US FDA For del-zota In DMD44
13/10/2025 14:03
Oct 13 (Reuters) - Avidity Biosciences Inc RNA.O: AVIDITY BIOSCIENCES ANNOUNCES POSITIVE PRE-BLA MEETING WITH U.S. FDA FOR DEL-ZOTA IN DMD44 WITH A SUBMISSION PLANNED FOR Q1 2026 AVIDITY BIOSCIENCES INC - BLA SUBMISSION FOR DEL-ZOTA UPDATED TO Q1 2026 Source text: ID:nPn1wBqfLa Further company coverage: RNA.O
Recent news on Avidity Biosciences
See all newsFactbox: Pharma sector doubles down on AI amid hopes of slashing costs, timelines
Factbox: Pharma sector doubles down on AI amid hopes of slashing costs, timelines
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:28 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:28 AM
Brief: Avidity Biosciences Says Record Date Set For February 12, 2026 For Spin-Off